CLINICAL_TRIALS trial_result · 2019-09-24

Clinical Trial Update: Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab [Phase 3]

Phase 3 trial evaluating efficacy and safety of daclizumab in RRMS patients switching from natalizumab; study terminated with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 | Status: TERMINATED | Results posted: 2019-09-24